Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Care of the pregnant woman with coronavirus disease 2019 in labor and delivery: anesthesia, emergency cesarean delivery, differential diagnosis in the acutely ill parturient, care of the newborn, and protection of the healthcare personnel

Balakrishnan Ashokka, FANZCA; May-Han Loh, MMED Anesthesiology; Cher Heng Tan, FRCR; Lin Lin Su, MRCOG; Barnaby Edward Young, MRCP; David Chien Lye, FRCP; Arijit Biswas, FRCOG; Sebastian E. Illanes, MD; Mahesh Choolani, FRCOG

Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 are the largest group of RNA viruses.1 COVID-19 has now been declared a pandemic by the World Health Organization (WHO). The elderly are at greatest risk.2 Current evidence suggests that neither are pregnant women at a greater risk of COVID-19 than other adults,3 nor is the condition thought to be more severe in them.4 A case series of 9 pregnant women at term and late preterm (36 weeks and above) reported good maternal and fetal outcomes.5 However, all these cases had short time intervals between the diagnosis of COVID-19 and cesarean deliveries, and the true impact of the disease on pregnant women should not be extrapolated from this descriptive study. Moreover, when a larger cohort of 147 pregnant patients was evaluated...
PaO2/FiO2 mission from the pregnant patient to the nesses, such as coronavirus pneumonia. poor outcomes during respiratory ill-
health systems with better systematic in
nancy was less than that observed during organ failure that requires intensive care). This rate of severe illness in pregnancy was less than that observed during the influenza (H1N1) pandemic. These statistics came from a country that is now recognized globally to be dealing admirably with the COVID-19 outbreak, having gained experience from the 2003 severe acute respiratory syndrome (SARS) epidemic. It is uncertain whether other health systems would experience severe maternal morbidity below 10% or instead severe illnesses in pregnant women closer to 25% as observed in other coronavirus infections such as the Middle East respiratory syndrome (MERS) and SARS.

Moreover, SARS-CoV-2 has been shown to have 85% similarity with SARS coronavirus (SARS-CoV) and MERS coronavirus (MERS-CoV). Both the SARS and MERS epidemics had significant adverse effects on pregnant women including preterm deliveries, stillbirths, respiratory complications, and maternal mortality. Preexisting physiological factors such as basal atelectasis from gravid uterus, lower lung reserves (reduced functional residual capacity), and increased oxygen consumption (30%) predispose the parturient to poor outcomes during respiratory illnesses, such as coronavirus pneumonia. However, there is reasonably good evidence to suggest that vertical transmission from the pregnant patient to the fetus is unlikely. Recommendations are in place for managing suspected or confirmed pregnant patients with COVID-19, ensuring the safety of their neonates, other parturients in the delivery suite, and healthcare workers caring for them.

Disease transmission and case fatality rate (2.3%) are known to be lower in health systems with better systematic pandemic preparedness strategies and experience in managing coronavirus outbreaks. As of March 25, 2020, Singapore has hospitalized 631 COVID-19 cases confirmed by real-time reverse transcription polymerase chain reaction (RT-PCR), 3 of which were pregnant. Of these 631 patients, 160 fully recovered from the infection and were discharged from hospital. There were 2 mortalities from complications owing to COVID-19, 1 of which was an imported patient who was ill before coming to Singapore and admitted to the intensive care unit (ICU) upon arrival. Singapore was taken by surprise during the 2003 SARS epidemic, but it has since built capacity and capability within the country to manage global infectious disease emergencies with standard protocols for nongravid and pregnant patients.

Clinical presentation
COVID-19 can present with a spectrum of clinical manifestations ranging from mild signs and symptoms, such as fever, cough, sore throat, myalgia, and malaise, to severe illness, such as pneumonia with or without acute respiratory distress syndrome (ARDS), renal failure, and multiorgan dysfunction that may require immediate advanced critical care support. Clinical presentations in pregnant patients with COVID-19 could be atypical with normal temperature (56%) and leukocytosis.

Clinical virology
The largest report to date on COVID-19 from China revealed 1% asymptomatic of 72,134 cases. Of the 44,672 cases confirmed by RT-PCR, 8% were aged between 20 and 29 years whereas 87% between 30 and 79 years. There was no further stratification in the 30 to 79 years age group to represent the reproductive age group 30 to 45 years. Of the 44,415 cases with data on clinical severity, 81% were classified as mild, 14% severe (dyspnea, tachypnea, or oxygen saturation ≤93%), and 5% critical (respiratory failure, septic shock, or multiorgan failure). Overall, case fatality was 2.3%, with 8% of patients in the age group of 70 to 79 years, 14.8% in 80 years and older, and 49% among critically ill. More detailed clinical information from 1099 patients revealed that fever was present in 43.8% on admission but developed in 88.7% during hospitalization. Cough was present in 67.8%, but sputum production was observed only in 33.7%, nasal congestion 4.8%, sore throat 13.9%, and diarrhea 3.8%. The median time from illness onset to dyspnea was 8 days, to ARDS 9 days, and ICU admission 10.5 days. Compared with non-ICU patients, ICU patients with COVID-19 were older with comorbidities and had higher temperature; more dyspnea and tachypnea; more leukocytosis, neutrophilia, and lymphopenia; and higher alanine and aspartate aminotransferase, bilirubin, creatinine, procalcitonin, troponin, D-dimer, and lactate dehydrogenase.

Diagnosing coronavirus disease 2019
Confirmation of the disease is done using nucleic acid amplification tests (NAATs), such as real-time RT-PCR. Average RT-PCR testing needs up to 2 hours, but it takes between 6 and 10 hours for completion, or even longer when batch testing is done by laboratories.

Chest imaging
Imaging of the lungs is important in assessing the extent of COVID-19 pneumonia and in follow-up. Evidence of consolidation is more frequently seen, whereas lower lobe chest CT, multilobar GGOs are most commonly seen, whereas lower lobe consolidation is more frequently observed in patients with severe and prolonged disease (Figure 1C and 1D).
Given its relatively untested specificity, its use as a first-line diagnostic tool has been discouraged by the American College of Radiology. In an epidemic setting where there is very high pretest probability of COVID-19 infection, a positive result on chest CT scan may precede RT-PCR and chest CT may have higher sensitivity for diagnosis. In a case series of 15 pregnant patients with COVID-19 who were exposed to ionizing radiation between
2.3 and 5.8 mGy, all were found to have CT findings of mild disease, which did not worsen with pregnancy. In some circumstances when an earlier diagnosis of COVID-19 would alter the management of an obstetric patient, particularly if the patient is in respiratory distress raising concerns about significant pneumonia or concomitant pathology (eg, pulmonary embolism), CXR, and thereafter chest CT if needed, could be considered. A diagnostic workflow detailing the application of RT-PCR and chest imaging in the assessment of suspected patients with COVID-19 is described (Figure 2). In such instances, abdominal lead shielding may be applied to reassure patients of the minute risks of scatter radiation to the fetus.

**Differential diagnosis**

COVID-19 is primarily a respiratory illness. As our understanding of the diagnostic imaging features of COVID-19 evolves, significant overlap with other viral and atypical pneumonias has been increasingly reported. On CXR, COVID-19 pneumonia often presents with multifocal, bilateral airspace opacification. This distinguishes it from the more common unifocal involvement noted in SARS, but not in MERS. When imaged by CT, the distribution seen in COVID-19 is similar to that noted in other viral and coronaviral pneumonias, such as influenza, parainfluenza, respiratory syncytial virus, and adenovirus. Even the multifocal GGOs, described in more than 80% of COVID-19 pneumonias, are common features of atypical (eg, Mycoplasma pneumoniae) and opportunistic (eg, Pneumocystis jirovecii) pneumonias. As with other viral pneumonias, lymphadenopathy and pleural effusions are uncommon associated findings. In the later stages of COVID-19, confluent consolidation and interstitial thickening become more pronounced, with up to 20% patients developing features of ARDS. Given the significant overlap of imaging findings with other acute viral
respiratory infections, imaging alone is unlikely to supplant the role of RT-PCR for the primary diagnosis of COVID-19.

Minimizing disease transmission

Person-to-person transmission is now known to occur via fomites, droplets through close proximity aerosols, and prolonged close contact within a 2-m perimeter. A study revealed that patients can continue to shed the virus as evidenced by positive RT-PCR results for up to 13 days after disease resolution. Stool sample remained positive in 50% of recovered patients. Coronavirus epidemics in the past are known to have occurred with aerosolization from flushing of toilets.

The spread of infection has been reported from asymptomatic patients, thereby rendering early detection and disease containment difficult. There is a possibility of viral dissemination when a patient is forcefully exhaling when in pain during active labor. Hence it is prudent to consider early epidural analgesia for optimal pain control, and unmedicated natural labor should be discouraged. In addition, all healthcare staff attending to women in active labor need to don full personal protective equipment (PPE).

Infection control

In a simulated experiment where aerosols were generated using a 3-jet Collison nebulizer and fed into a Goldberg drum, SARS-CoV-2 could survive on plastic and stainless steel surfaces for 72 hours, cardboard 24 hours, and copper 4 hours. The median half-life of the virus in this simulated aerosol was 2.7 hours (95% confidence interval, 1.65—7.24 hours).

In contrast, in a real-world experiment conducted in Singapore, 3 patients in different rooms had surface environmental samples taken at multiple sites, which revealed that bleach disinfection was highly effective in 2 rooms and fomite contamination was common in the third room. Notably, air, PPE, anteroom, and corridor samples were negative. In addition, a case report of emergency intubation in an unsuspected patient subsequently found to have a positive test result for COVID-19 showed that no healthcare workers wore surgical or N95 masks were infected. In summary, current recommendations for hand hygiene, eye protection, N95 mask, splash-resistant gown, and gloves should be sufficient.

Managing patients with coronavirus disease 2019 in labor

A pregnant woman presenting to the delivery suite or emergency department needs to be triaged based on the presence of maternal and/or fetal compromise (Figure 2). When there is imminent risk, emergency cesarean delivery must be performed. When there are other maternal and fetal conditions requiring early operative delivery, a coordinated team response is initiated for assessment and optimization of maternal oxygenation and infection control measures. Cesarean delivery is advised for maternal indications, such as worsening condition of the mother related to COVID-19 and fulminant preeclampsia, or fetal indications, such as nonreassuring fetal status. When an operative delivery is not planned, pregnant mothers need to be admitted into the delivery suite for detailed assessment, labor pain management, stratification of infection control precautions, and plans for safe delivery of the fetus. In the presence of COVID-19, the threshold for cesarean delivery should be lower than usual so that infection control procedures can be more readily adhered to and disease transmission minimized.

Anesthesia in emergency cesareans for pregnant women with coronavirus disease 2019

An emergency cesarean delivery (30-min decision-to-incision interval) mandates a systematic plan and preparedness for minimizing cross-contaminations. Although emergency cesarean delivery needs to be performed as soon as possible, there are instances where the decision to go for urgent cesarean delivery has some lead time. The possibilities of suspected patients with COVID-19 requiring imminent operative deliveries have to be communicated to the operating room team so that they could be conducted in negative-pressure operating rooms.

When a COVID-19 parturient with desaturation (oxygen saturation decreases to ≤93%) presents for emergency cesarean delivery, general anesthesia needs to be administered, which is done with rapid sequence induction (RSI) and tracheal intubation with a cuffed tube. The airway team should don full PPE and powered air-purifying respirator (PAPR). The presence of systemic complications of COVID-19 such as renal failure and disseminated intravascular coagulation might warrant the use of invasive monitoring (intra-arterial blood pressure and central venous pressure).

When the parturient’s oxygen saturation is adequate (94% and above), regional anesthesia with epidural top-up or single-shot subarachnoid blockade needs to be actively considered instead of general anesthesia to minimize aerosolization and cross-infection during airway management. Where there is a working epidural catheter in place for continuous labor analgesia, administering a top-up with potent local anesthetics (eg, 10—15 mL of 1.5% lignocaine, alkalinized with 8.4% sodium bicarbonate) achieves surgical anesthetic plane with a rapid onset of 3.5 minutes. Rapid sequence spinal anesthesia is described for emergency cesarean deliveries, wherein patients are placed in a left lateral position with supplemental oxygen, and a single-shot subarachnoid blockade is administered by the most experienced prescrubbed anesthetist. The time required for surgical readiness is comparable with that for general anesthesia, and neonatal outcomes are better.

Exubation after general anesthesia should be performed with the same
pa- 

42 During RSI and intuba-

41 In the event of respiratory arrest, surgical airway management must be undertaken as soon as possible. Precautions as with intubation.41 Patients tend be more agitated during emergence from anesthesia and extuba-

42 It is imperative that all operating room personnel wear full PPE until patients are safely extubated and transferred out of the operating room.38,41

43 The disposition for patients with COVID-19 after unplanned cesarean de-

44 The percentage saturation of hemoglobin with oxygen (SpO2) is a noninvasive continuous monitoring that provides real-time information on peripheral oxygen satu-

45 The acutely ill parturient

46 A stepwise approach for systematic man-

47 If there is absence of maternal and/or fetal compromise, and emergency cesar-ean delivery is not indicated, further plans for management of patients are then made (Figure 3). When parturients are acutely ill, it may be challenging to differentiate etiologies based on the presence of tachypnea and tachycardia. The percentage saturation of hemoglobin with oxygen (SpO2) is a noninvasive continuous monitoring that provides real-time information on peripheral oxygen saturation. It also provides indirect information on adequacy of pulmonary gas exchange, cardiac function, and intravas-

48 The percentage saturation of hemoglobin with oxygen (SpO2) is a noninvasive continuous monitoring that provides real-time information on peripheral oxygen satu-

49 The stepwise approach for systematic management of the acutely ill parturient is detailed (Figure 3).

50 When SpO2 has decreased to less than 94%, rapid clinical decisions must be made in the context of COVID-19.
Hypotensive patients with low \( \text{SpO}_2 \) must be prioritized and systematically managed at the earliest, taking into consideration cardiac, noncardiac, and septic causes.

Bedside transthoracic echocardiography (TTE) is a practical and swift method for the assessment of hypotension.\(^4\) A poorly contractile left ventricle signifies cardiac pump failure. In this case, fluids should be restricted and the use of inotropes should be considered. Hyperdynamic cardiac activity as evidenced by “kissing” ventricular walls is suggestive of distributive shock such as in sepsis. This requires fluid resuscitation and the use of vasopressors. To assess the patient’s intravascular volume status, TTE probe can also be used to image the inferior vena cava (IVC). Avoidance of fluid mismanagement is crucial; fluid loading in cardiomyopathy can precipitate congestive cardiac failure that worsens lung oxygenation.

Cardiovascular causes of desaturation in COVID-19 include systolic failure from viral myocarditis, congestive cardiac failure, and pulmonary edema. The SARS-CoV-2 surface glycoprotein interacts with angiotensin-converting enzyme 2 (ACE2) of the respiratory epithelial cells of the host. The predominant pulmonary features are from the ACE2 expression in type 2 alveolar cells. Elevated blood pressure is known to occur from interaction between the virus and ACE2.\(^5\) This might result in misdirected management toward preeclampsia, whereas hypertension is a cardiovascular manifestation of COVID-19. Myocardial injury as evidenced by raised troponin levels is a feature of cytokine storms,\(^4\) that is, high concentrations of granulocyte-colony stimulating factors (GCSFs), interferon gamma—induced protein \( 10 \) (IP10), monocyte chemottractant protein \( 1 \) (MCP1), macrophage inflammatory protein \( 1 \alpha \) (MIP1\( \alpha \)), and tumor necrosis factor alpha (TNF-\( \alpha \)).\(^6\) Cytokine storms are known to be associated with disease severity and ICU admissions.\(^7,4\)

Morbid manifestations of COVID-19 such as severe pneumonia, ARDS, and multiorgan dysfunction syndrome (MODS) require advanced ventilatory and circulatory support.\(^1\) When patients present with hypoxemia, it is important to differentiate between failure of gas exchange in the lungs and cardiogenic causes of pump failure.\(^3\) Pulmonary causes of desaturation from pneumonia, acute lung injury, and ARDS are more difficult to manage because they may require prolonged mechanical ventilation.

Pressurized air enriched with oxygen is needed for improving oxygenation in acutely ill patients with respiratory compromise. It can be administered via nasal masks, full face masks, and helmets. Simulation-based experiments have shown the effectiveness of continuous positive airway pressure (CPAP) with tight fitting oronasal mask and noninvasive ventilation with well-sealed helmets, posing negligible risk of exhaled air dispersion.\(^6\) Similar studies have shown that exhaled air dispersion distance during application of high-flow nasal cannula is shorter than CPAP that tends to be applied less tightly.\(^3\) Hence, centers that are experienced and equipped with negative-pressure rooms could consider noninvasive ventilation, high-flow nasal cannula, and CPAP, especially during the COVID-19 pandemic when facilities with full mechanical ventilatory support are overwhelmed.

Where the patient’s oxygen saturation is refractory to mechanical ventilatory support, extracorporeal membrane oxygenation (ECMO)\(^5\) should be considered. Initiating ECMO in a pregnant patient needs special considerations. Although anticoagulation is needed to prevent clotting in the extracorporeal circulation, this complicates hemostasis at the placental site if ECMO is used in the peripartum period. ECMO setup requires multidisciplinary planning and is best done in tertiary institutions. Maternal and child health facilities without cardiac surgical ICUs might not be able to acquire this service. The transfer of critically ill patients to tertiary institutions needs meticulous planning.

**Drugs and evolving therapy for coronavirus disease 2019**

**Antiviral treatment**

Much of the early information on COVID-19 treatment was derived from experience in SARS. Data on the use of antiviral therapy for COVID-19 in pregnancy are limited.\(^5\) In SARS, ribavirin and corticosteroid showed possible harm with inconclusive clinical data, whereas studies on convalescent plasma, interferon, and lopinavir were inconclusive.\(^5\) In the first randomized controlled trial on COVID-19 treatment, 400-mg/100-mg lopinavir-ritonavir twice daily was found to be similar to the standard of care in time to clinical improvement, mortality, and viral shedding.\(^5\) This may be due to differences in viral proteases between HIV and coronavirus.\(^5\) An in vitro study on repurposed drugs for COVID-19 reported effective concentration 50 (EC50) of 0.77 for remdesivir, 1.13 for chloroquine, 61.88 for favipiravir, and 109.50 for ribavirin.\(^5\) EC50 for hydroxychloroquine was significantly higher than chloroquine.\(^5\) In a French nonrandomized study,\(^5\) 26 patients received 200-mg hydroxychloroquine thrice daily for 10 days, 6 of whom also received azithromycin 500 mg on day 1 and 250 mg daily for the next 4 days. Compared with 16 untreated patients, there was significant reduction in viral load at day 6 and shorter duration of viral shedding, with additive effect from azithromycin. In a Chinese nonrandomized study,\(^5\) 35 patients were treated with favipiravir 1600 mg twice daily on day 1 and 600 mg twice daily from days 2 to 14 and 45 patients were treated with lopinavir-ritonavir; patients in both arms received aerosolized interferon alfa (IFN-\( \alpha \)) 5 million units twice daily. Compared with control, favipiravir was associated with shorter viral shedding and faster radiologic improvement.

The delivery suite and considerations for minimizing cross-contamination

Enhanced infection control precautions include restrictions on the number of personnel in the delivery suite to minimize cross-contaminations, movements between care locations, and the number of external visitors and care providers.\(^5\) The care for the parturient should be specialist led. When there is a suspected or confirmed case of COVID-19, delivery processes such as water birth need
to be revised to limit the potential spread of infection. In addition, strict adherence to policies for segregations of teams deployed in delivery suite, general ward, procedure rooms, and outpatient units is recommended.\(^5\) The workflow on peripartum management of COVID-19 women is detailed in the Appendix.

Labor analgesia can be planned well in advance such that when patients are in early labor, they receive good pain control through initiation of epidural analgesia.\(^10\) This reduces chances of viral disseminations during hyperventilation when the parturient is in pain, thereby reducing the risk of cross-contamination between staff and patients.\(^25\) Inhaled entonox is not recommended\(^10\) because it could increase the risk of viral dissemination through aerosols, especially when the parturient is not able to achieve tight uninterrupted mask seal throughout the duration of labor.\(^12,48,49\)

**Care of newborn of COVID-19 mothers**

Current evidence shows that there is no vertical transmission during pregnancy.\(^2,9\) However, babies born to mothers with COVID-19 can acquire the infection after delivery. Practices such as delayed cord clamping and skin-to-skin bonding between mothers and newborns are not recommended. The evidence regarding the safety of breastfeeding is still limited.\(^2,25,90\) Considerations can be made to allow the use of screened donated breast milk from COVID-19–free mothers.

The process of segregation is simple when the newborn is healthy. However, the process becomes more complicated when there is perinatal asphyxia or need for ventilatory support. Finding an isolation unit for the newborn who requires continuous monitoring is a challenge. Specific care locations for newborns of mothers with COVID-19 have to be designated in advance; care teams need to be trained on workflow and infection control measures.

**Maternal collapse and perimortem delivery**

In the unfortunate event of maternal collapse, it can be challenging to regulate and adapt all aspects of infection prevention. The delivery suite is overwhelmed when many personnel simultaneously attempt to resuscitate the collapsed patient, perform a perimortem cesarean delivery, and resuscitate the newborn. The resuscitation team should don full PPE. The most common occurrence of serious cross-infections to healthcare workers during outbreaks was in crisis situations when first responders were not wearing the recommended PPE.\(^1\)

**Summary**

The number of cases of COVID-19 continues to rise exponentially in many parts of the world. Pregnant women at all gestational ages are counted among this increase, and the gravida in labor and the acutely ill parturient are at the greatest risk. When the woman in labor needs an emergency cesarean delivery or the plan is to achieve a vaginal birth, she and the health support team face many unique challenges. We present here the best evidence available to address many of these challenges, from making the diagnosis in symptomatic cases to the debate between nucleic acid testing and chest imaging and to the management of ill patients in labor. There is reasonably good evidence that vertical transmission is unlikely, and efforts must be taken to prevent infection of the neonate. Given the limited knowledge about this novel coronavirus, which has both similarities and differences to SARS and MERS, the management strategies provided here are a general guide based upon current available evidence and may change as we continue to learn more about the effect of COVID-19 in pregnant women.

**ACKNOWLEDGMENTS**

We acknowledge the pediatric infectious diseases inputs from Dr Chan Si Min, Pediatrics, National University Hospital Singapore. The authors thank Dr Pradip Dashraath and Dr Wong Jing Lin Jeslyn, Department of Obstetrics and Gynecology, National University Hospital Singapore, for their inputs during the initial discussion about the direction of the manuscript.

**REFERENCES**

1. Schwartz DA, Graham AL. Potential maternal and infant outcomes from (Wuhan) coronavirus 2019-nCoV infecting pregnant women: lessons from SARS, MERS, and other human coronavirus infections. Viruses 2020;12:194.
2. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507–13.
3. Rasmussen SA, Smulian JC, Lednicky JA, et al. Coronavirus disease 2019 (COVID-19) and pregnancy: what obstetricians need to know. Am J Obstet Gynecol 2020 [Epub ahead of print].
4. Qiao J. What are the risks of COVID-19 infection in pregnant women? Lancet 2020;395:760–2.
5. Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet 2020;395:809–15.
6. World Health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). Available at: https://www.who.int/docs/default-source/coronovirus/who-china-joint-mission-on-covid-19-final-report.pdf. Accessed March 16, 2020.
7. Wong SF, Chow KM, Leung TN, et al. Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome. Am J Obstet Gynecol 2004;191:292–7.
8. Tan BK, Tan EL. Alterations in physiology and anatomy during pregnancy. Best Pract Res Clin Obstet Gynaecol 2013;27:791–802.
9. Zhu H, Wang L, Fang C, et al. Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia. Transl Pediatr 2020;9:51–60.
10. Royal College of Obstetricians and Gynaecologists. Coronavirus (COVID-19) infection in pregnancy. Available at: https://www.rcog.org.uk/en/guidelines-research-services/guidelines/coronavirus-pregnancy/covid-19-virus-infection-and-pregnancy/. Accessed March 22, 2020.
11. Poon LC, Yang H, Lee JCS, et al. ISUOG interim guidance on 2019 novel coronavirus infection during pregnancy and puerperium: information for healthcare professionals. Ultrasound Obstet Gynecol 2020 [Epub ahead of print].
12. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020 [Epub ahead of print].
13. Wong JEL, Leo YS, Tan CC. COVID-19 in Singapore—current experience: critical global issues that require attention and action. JAMA 2020 [Epub ahead of print].
14. Ministry of Health. Singapore. Passing of two patients with COVID-19 infection. Available at: https://www.moh.gov.sg/news-highlights/details/passing-of-two-patients-with-covid-19-infection. Accessed March 23, 2020.
15. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel
coronavirus in Wuhan, China. Lancet 2020;395:497–506.
16. Liu H, Liu F, Li J, Zhang T, Wang D, Lan W. Clinical and CT imaging features of the COVID-19 pneumonia: focus on pregnant women and children. J Infect 2020 [Epub ahead of print].
17. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020 [Epub ahead of print].
18. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020 [Epub ahead of print].
19. National University of Singapore, Saw Swee Hock School of Public Health. SSHSPH COVID-19 science reports: diagnostics. Available at: https://ssh.nus.edu.sg/wp-content/uploads/2020/03/Covid-19-Science-Report-Diagnostics-23-Mar.pdf. Accessed March 23, 2020.
20. Hosseiny M, Kooraki S, Gholamrezaehad A, Reddy S, Myers L. Radiology perspective of coronavirus disease 2019 (COVID-19): lessons from severe acute respiratory syndrome and Middle East respiratory syndrome. AJR Am J Roentgenol 2020 [Epub ahead of print].
21. Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis 2020;20:425–34.
22. Liu D, Li L, Wu X, et al. Pregnancy and perinatal outcomes of women with coronavirus disease (COVID-19) pneumonia: a preliminary analysis. AJR Am J Roentgenol 2020 [Epub ahead of print].
23. Ai T, Yang Z, Hou H, et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology 2020 [Epub ahead of print].
24. American College of Radiology. American College of Rheumatology Research and Education Foundation. ACR-SPR practice parameter for imaging pregnant or potentially pregnant adolescents and women with ionizing radiation. Reston, VA: American College of Radiology; 2013.
25. Yang H, Wang C, Poon LC. Novel coronavirus infection and pregnancy. Ultrasound Obstet Gynecol 2020;55:435–40.
26. Wong KT, Antonio GE, Hui DS, et al. Severe acute respiratory syndrome: radiographic appearances and pattern of progression in 138 patients. Radiology 2003;228:401–6.
27. Das KM, Lee EY, Al Jawder SE, et al. Acute Middle East respiratory syndrome coronavirus: temporal lung changes observed on the chest radiographs of 55 patients. AJR Am J Roentgenol 2015;205:W267–74.
28. Miller WT Jr, Mickus TJ, Barbosa E Jr, Mullin C, Van Deering VM, Shilley KT, CT of viral lower respiratory tract infections in adults: comparison among viral organisms and between viral and bacterial infections. AJR Am J Roentgenol 2011;197:1088–95.
29. Marchiori E, Zanetti G, D’ippolito G, et al. Swine-origin influenza A (H1N1) viral infection: thoracic findings on CT. AJR Am J Roentgenol 2011;196:W233–8.
30. Salehi S, Abedi A, Balakrishnan S, Gholamrezaehad A. Coronavirus disease 2019 (COVID-19): a systematic review of imaging findings in 919 patients. AJR Am J Roentgenol 2020 [Epub ahead of print].
31. Koo HJ, Lim S, Cho J, Choi SH, Sung H, Do KH. Radiographic and CT features of viral pneumonia. Radiographics 2018;38:719–39.
32. Franquet T. Imaging of pulmonary viral pneumonia. Radiology 2011;260:18–39.
33. Chiauzzi M, Davis JT, Aiji M, et al. The effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-19) outbreak. Science 2020 [Epub ahead of print].
34. van Doremalen N, Bushmasher T, Morris DH, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med 2020 [Epub ahead of print].
35. Ong SWX, Tan YK, Chia PY, et al. Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient. JAMA 2020 [Epub ahead of print].
36. Ng K, Poon BH, Keat Puar TH, et al. COVID-19 and the risk to health care workers: a case report. Ann Intern Med 2020 [Epub ahead of print].
37. AAP Committee on Fetus and Newborn, ACOG Committee on Obstetric Practice, Kilpatrick SJ, Papile LA, Macones GA. Guidelines for perinatal care, 8th edition. Elk Grove, IL: American Academy of Pediatrics; 2017.
38. Tiuk J, Ang LS, Foong TW, Ng BSW. What we do when a COVID-19 patient needs an operation: do when a COVID-19 patient needs an operation: AJR Am J Roentgenol 2020 [Epub ahead of print].
39. Kinlessa SM, Girir磁场 J, Scrutton MJ. Rapid analysis of obstetric anesthesia on maternal and neonatal outcomes. Anesthesiology 2018;129:132–215.
40. Lin G, Facco FL, Nathan N, Waters JH, Wong GA, Ellsztigh HK. A review of the impact of obstetric anesthesia on maternal and neonatal outcomes. Anesthesiology 2018;129:664–9.
41. Vin RL, Eltzschig HK. A review of the impact of obstetric anesthesia on maternal and neonatal outcomes. Anesthesiology 2018;129:664–9.
42. Vin RL, Eltzschig HK. A review of the impact of obstetric anesthesia on maternal and neonatal outcomes. Anesthesiology 2018;129:664–9.
Appendix
Peripartum management of women with COVID-19

Antenatal management

Patient will be admitted to isolation ward with negative-pressure room.

Teams to be activated upon admission to isolation ward

- Primary physician
- Maternal-fetal medicine team
- Neonatology team and pediatric infectious diseases team
- Pediatric intensive care unit team
- Anesthesia team
- Infectious diseases team
- Nursing team
- Operating theater team
- Medical social worker

If steroids administration is considered, the decision will be made following joint discussion by obstetrics, neonatology, and infectious disease teams.

Items to be discussed and completed in the antenatal ward:

- The aim is normal vaginal delivery.
- Discuss with patient regarding the delivery process and postpartum care.
- To inform patient that baby will be separated immediately after delivery and will be admitted to PICU. COVID-19 testing will be carried out on the baby.
- If the test result is positive, the baby will stay with the mother.
- If the test result is negative, the baby will remain isolated.
- Consent forms for normal vaginal delivery, assisted vaginal delivery, and cesarean delivery need to be signed.
- Strongly recommend early epidural analgesia to minimize the need for general anesthesia in the event of emergency cesarean delivery.
- Informed consent for labor epidural analgesia needs to be preobtained and be reverified at time of procedure.
- Strictly no use of entonox due to the risk of aerosolization.

Intrapartum management

Once labor starts, patient is to be transferred from the isolation ward to the isolation room in the delivery suite. If the isolation room in the delivery suite is not available, the patient will be transferred to the medical intensive care unit for delivery.

Teams to activate once patient arrives in delivery suite:

- Overall coordinator
- Primary obstetrician
- Neonatology team — consultant and neonatology registrar on call — who will contact pediatric infectious diseases and pediatric intensive care unit teams
- Anesthesia — obstetric anesthesia (epidural consultant on call)
- Operating theater nurse in charge
- Infectious diseases team consultant
- Coordinator for clinical sample collection
- Team to wear full PPE/PAPR during delivery in the isolation room in the delivery suite.
- Designated nurse assigned to the patient. Nurse in charge/sister is the second assistant.
- Medical staff to manage the case will be consultants and/or registrars and not junior residents.
- The practice of delay cord clamping and skin-to-skin bonding between the mother and newborn is not recommended.
- Should an emergency cesarean delivery be needed, designated operating room should be used. There are 2 designated operating rooms (operating room nurse in charge will inform the operating room upon being activated).
- Please refer to the routes from the delivery suite or medical ICU to operating theater.

Ashokka. Care of the pregnant woman with coronavirus disease 2019 in labor and delivery. Am J Obstet Gynecol 2020.
Clinical samples to be collected at the time of delivery (perinatal) — full PPE for sample collection. This may vary depending on clinical needs and facilities available at each center.

- High vaginal swab #1 — PCR
- High vaginal swab #2 — PCR
- Amniotic fluid (in specimen bottle) — PCR
- Maternal blood — 1 EDTA tube, 1 plain tube — PCR
- Umbilical cord blood — additional 1—2 mL for PCR (EDTA tube)
- Placenta — fetal surface swab (1 swab) — PCR
- Placenta — maternal surface swab (1 swab) — PCR
- Umbilical cord — external surface of the cord (1 swab) — PCR
- Umbilical cord — intravascular surface (1 swab, from inside UA or UV) — PCR
- Placenta — full-thickness biopsy (include fetal and maternal surfaces — to put stitch in maternal surface) — for histology
- Umbilical cord at the insertion site — full-thickness segment — for histology

Disposal of placenta — placenta is to be placed in triple biohazard bags before disposal. If cesarean delivery is performed, placenta is to be disposed in the Operating Theater.

Postpartum management

After delivery:
- Baby will be immediately transferred to pediatric intensive care unit.
- Patient will be transferred back to the isolation ward.
- Transfer will be as per hospital protocol.
- Upon completion of transfer, medical and nursing staff need to shower and change to a new set of scrub uniform for the next case.
- Book cleaning team needs to disinfect the room as per infection control protocol (turnaround time: up to 3 hours for the next availability of bed).

COVID-19: coronavirus disease 2019; EDTA, ethylenediamine tetraacetic acid; ICU, intensive care unit; PAPR, powered air-purifying respirator; PICU, pediatric intensive care unit; PCR, polymerase chain reaction; PPE, personal protective equipment.

Ashokka. Care of the pregnant woman with coronavirus disease 2019 in labor and delivery. Am J Obstet Gynecol 2020.
GLOSSARY

ACE2: angiotensin-converting enzyme 2 (the functional receptor of SARS-CoV-2)
AFE: amniotic fluid embolism
ARDS: acute respiratory distress syndrome
CO: cardiac output measured by noninvasive pulse contour methodology from intra-arterial waveform analysis
COVID-19: coronavirus disease 2019 (previously called 2019 novel coronavirus [2019-nCoV])
CT: computed tomography
CXR: chest X-ray
ECMO: extracorporeal membrane oxygenation
EC50: effective concentration 50 (concentration of a drug that gives half maximal response)
Emergency cesarean delivery: operative delivery that is to be conducted within 30 minutes after the decision is made for the surgery
FiO2: fraction of inspired oxygen
Functional residual capacity: volume of air in the lungs at the end of expiration; it is the sum of residual volume and end expiratory volume
GA: general anesthesia
GCSF: granulocyte-colony stimulating factor
GGO: ground glass opacity
ICU: intensive care unit
IFN-α: interferon alfa
IP10: interferon gamma-inducible protein 10
IVC: inferior vena cava
LV: left ventricle
MCP1: monocyte chemoattractant protein 1
MIP1α: macrophage inflammatory protein 1 alfa
MERS: Middle East respiratory syndrome
MERS-CoV: Middle East respiratory syndrome coronavirus
MODS: multiorgan dysfunction syndrome
NAAT: nucleic acid amplification test
Negative-pressure room: room that maintains a lower air pressure inside the treatment area than that of the surrounding environment
NIV: noninvasive ventilation
N95 mask: respiratory protective device that removes at least 95% of very small (0.3 micron) test particles; the American equivalent of an FFP2 respirator
PACU: postanesthesia care unit
PaO2: arterial partial pressure of oxygen
PAPR: powered air-purifying respirator
PaO2/FiO2 ratio: ratio between arterial pressure of oxygen (PaO2) and fraction of inspired oxygen (FiO2)
PPE: personal protective equipment
RA: regional anesthesia
RSI: rapid sequence induction
RT-PCR: reverse transcription polymerase chain reaction
RV: right ventricle
SARS: severe acute respiratory syndrome
SARS-CoV: severe acute respiratory syndrome coronavirus—virus that causes SARS
SARS-CoV-2: severe acute respiratory syndrome coronavirus-2 virus—virus that causes COVID-19
SpO2: percentage saturation of hemoglobin with oxygen
Suspect case of COVID-19: a patient who presents with an acute respiratory illness of any degree of severity who, within 14 days before onset of illness had traveled to any listed countries requiring heightened vigilance, or had prolonged close contact with a confirmed COVID-19 patient
SVR: systemic vascular resistance
TNF-α: tumor necrosis factor alpha
TTE: transthoracic echocardiography
WHO: World Health Organization